Diagnostic value of soluble mesothelin in malignant mesothelioma [3]

Thorax

Volumn 63, Issue 1, 2008, Pages 87-88

  Grigoriu, B D ^a   Scherpereel, A ^b  

^a GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

MESOTHELIN; MEGAKARYOCYTE POTENTIATING FACTOR; MEMBRANE PROTEIN; UNCLASSIFIED DRUG;

CANCER DIAGNOSIS; CANCER RESEARCH; CANCER STAGING; CLINICAL PRACTICE; DIAGNOSTIC VALUE; DISEASE MARKER; HISTOLOGY; HUMAN; LETTER; PLEURA EFFUSION; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROGNOSIS; TUMOR VOLUME; MESOTHELIOMA; METABOLISM; NOTE;

HUMANS; MEMBRANE GLYCOPROTEINS; MESOTHELIOMA; PROGNOSIS;

EID: 38349138511     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (5)

1. Creaney J, Yeoman D, Naumoff LK, et al. Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma. Thorax 2007;62:569-76.
2. Lee YCG. Hunting for a pleural fluid test for mesothelioma: is soluole mesothelin the answer? Thorax 2007;62:561-2.
3. Robinson BW, Creaney J, Lake R, et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 2003;362:1612-6.
4. Scherpereel A, Grigoriu B, Conti M, et al. Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med 2006;173:1155-60.
5. Grigoriu BD, Scherpereel A, Devos P, et al. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. Clin Cancer Res 2007;13:2928-35.